Inactive Instrument

International Isotopes Inc. Stock Other OTC

Equities

INIS

US45972C1027

Industrial Machinery & Equipment

Sales 2022 11.18M 15.29M Sales 2023 12.27M 16.78M Capitalization 20.79M 28.44M
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 2.01 x
Net Debt 2022 5.74M 7.85M Net Debt 2023 5.66M 7.74M EV / Sales 2023 2.16 x
P/E ratio 2022
54.8 x
P/E ratio 2023
-23.8 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 28.59%
More Fundamentals * Assessed data
Dynamic Chart
International Isotopes, Inc. and Alpha Nuclide Inc Signs Strategic Development and Distribution Agreements for China CI
International Isotopes Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
An unknown buyer has entered into an Asset Purchase Agreement to acquire Unused assets in FEP business of International Isotopes Inc for $12.5 million. CI
International Isotopes Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
International Isotopes Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
International Isotopes Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
International Isotopes Inc. Announces Executive Changes CI
International Isotopes Inc. Appoints Shahe Bagerdjian to Serve as a Member of the Board CI
International Isotopes Inc. acquired Nuclear lung ventilation product line from Amici Inc. CI
Earnings Flash (INIS) INTERNATIONAL ISOTOPES Reports Q1 EPS $0.00 MT
International Isotopes Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
International Isotopes Inc. Announces Shahe Bagerdjian Appointed as President of the Company, Effective Immediately CI
International Isotopes Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
International Isotopes Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
International Isotopes Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 23-05-07
Director of Finance/CFO 40 19-03-31
Director/Board Member 67 01-05-31
Members of the board TitleAgeSince
Chairman 56 02-04-23
Director/Board Member 67 01-05-31
Director/Board Member 72 17-08-01
More insiders
International Isotopes Inc. manufactures a range of radioisotope-focused products. The Company’s segments include Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Device Products, and Fluorine Products. The Theranostics Products segment includes production and distribution of its generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. The Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications, and recycling of expended cobalt sources. The Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications.
More about the company